Citations

Clear

1011 citation(s) found for "Barry, WT".

Evaluation of Extended Infusion Set Performance in Adults with Type 1 Diabetes: Infusion Set Survival Rate and Glycemic Outcomes from a Pivotal Trial
Brazg, Ron, Bhargava, Anuj , Thrasher, James, Latif, Kashif, Bode, Bruce W. , Bailey, Timothy S. , Horowitz, Barry , Cavale, Arvind R., Kudva, Yogish C. , Kaiserman, Kevin B. , Grunberger, George , Reed, John Chip, CHATTARAJ, SARNATH , ZHANG, GINA , Shin, John , Chen, Vivian , Lee, Scott W., Cordero, Toni L. , Rhinehart, Andrew S., Buckingham, Bruce A. , Bailey, Timothy S , Horowitz, Barry S , Kudva, Yogish C. , Cordero, Toni L , Vigersky, Robert A , Buckingham, Bruce , Garg, Satish K. , Reed, John H. Chip, Vigersky, Robert A.

Mayo Clinic

Diabetes Technology & Therapeutics | March 9, 2022 | Volume: 24 | Issue: 8 | Pages: 535-543

10.1089/dia.2021.0540 | PMID 35263188 Get It

Background: Standard insulin infusion sets (IISs) are to be replaced every 2 to 3 days to avoid complications and diabetic ketosis due to set failure. This pivotal trial evaluated the safety and performance of a new extended-wear infusion set (EIS) when used for 7 days by adults with type 1 diabetes (T1D). Methods: This single-arm, nonrandomized trial enrolled adults (18–80 years of age) with T1D, who used their own MiniMed™ 670G system with insulin lispro or insulin aspart and the EIS for up to 7 days, across 12 consecutive wears. Safety endpoints included incidence of serious adverse events (SAEs), serious adverse device effects (SADEs), unanticipated adverse device effects (UADEs), severe hypoglycemia (SevHypo), severe hyperglycemia (SevHyper), diabetic ketoacidosis (DKA), and skin infection. The EIS failure rate due to unexplained hyperglycemia (i.e., suspected occlusion), the overall EIS survival rate, glycemic control outcomes (i.e., A1C, mean sensor glucose and time spent in established glucose ranges), total daily insulin delivered, and satisfaction with the EIS were determined. Results: The intention to treat population ( n = 259, 48% men, 45.0 ± 14.1 years) wore a total of 3041 EIS devices. No SADE, UADE, or DKA events was reported. Overall rates of SAEs, SevHypo, SevHyper, and skin infection were 3.8, 2.5, 104.1, and 20.1 events per 100 participant-years. The rate of EIS failure due to unexplained hyperglycemia at the end of day 7 was 0.1% (95% confidence interval [CI]: 0.03–0.51) and 0.4% (95% CI: 0.16–1.00) for insulin lispro and aspart use, respectively. Overall EIS survival rate at the end of day 7 was 77.8% (95% CI: 76.2–79.3), glycemic control did not change, and participants reported greater satisfaction with the EIS compared with standard IISs worn before the study ( P < 0.001). Conclusions: This investigation demonstrates that the EIS, when worn for up to 7 days, was safe and rated with high satisfaction, without adversely affecting glycemic control in adults with T1D. Clinical Trial Registration number: NCT04113694 ( https://clinicaltrials.gov/ct2/show/NCT04113694 ).
Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group
Crane, Jacquelyn , Xue, Wei , Qumseya, Amira, Gao, Zhengya, Arndt, Carola A.S., Donaldson, Sarah S. , Harrison, Douglas J. , Hawkins, Douglas S. , Linardic, Corinne M. , Mascarenhas, Leo , Meyer, William H. , Rodeberg, David A. , Rudzinski, Erin R. , Walterhouse, David , Venkatramani, Rajkumar , Crane, Jacquelyn N , Shulkin, Barry L , Hawkins, Douglas S , Donaldson, Sarah S , Mascarenhas, Leo , Shulkin, Barry L. , Weiss, Aaron R.

Mayo Clinic

Pediatric Blood & Cancer | March 6, 2022 | Volume: 69 | Issue: 6 | Pages: No page available

10.1002/pbc.29644 | PMID 35253352 Get It

Abstract The Children's Oncology Group (COG) uses Clinical Group (CG) and modified Tumor Node Metastasis (TNM) stage to classify rhabdomyosarcoma (RMS). CG is based on surgicopathologic findings and is determined after the completion of initial surgical procedure(s) but prior to chemotherapy and/or radiation therapy. The modified TNM stage is based on clinical and radiographic findings and is assigned prior to any treatment. These systems have evolved over several decades. We review the history, evolution, and rationale behind the current CG and modified TNM classification systems used by COG for RMS. Data from the seven most recently completed and reported frontline COG trials (D9602, D9802, D9803, ARST0331, ARST0431, ARST0531, ARST08P1) were analyzed, and confirm that CG and modified TNM stage remain relevant and useful for predicting prognosis in RMS. We propose updates based on recent data and discuss factors warranting future study to further optimize these classification systems.
Influence of locomotor muscle group III/IV afferents on cardiovascular and ventilatory responses in human heart failure during submaximal exercise
Smith, Joshua R. , Joyner, Michael J. , Keller‐Ross, Manda L. , Iterson, Erik H. Van , Olson, Thomas P. , Curry, Timothy B. , Van Iterson, Erik H , Smith, Joshua R , Joyner, Michael J , Keller-Ross, Manda , Borlaug, Barry A.

Mayo Clinic

Journal of Applied Physiology | February 24, 2022 | Volume: 132 | Issue: 4 | Pages: 903-914

10.1152/japplphysiol.00371.2021 | PMID 35201931 Get It

Patients with HFrEF exhibit severe exercise intolerance. One of the primary peripheral mechanisms contributing to exercise intolerance in patients with HFrEF is locomotor muscle group III/IV afferent feedback. However, it is unknown whether these afferents impact the central and peripheral responses during submaximal cycling exercise. Herein, we demonstrate that inhibition of locomotor muscle group III/IV afferent feedback elicited increases in stroke volume during submaximal exercise in HFrEF, but not in healthy controls.
Refined Capsid Structure of Human Adenovirus D26 at 3.4 Å Resolution
Reddy, Vijay , Yu, Xiaodi , Barry, Michael A. , Reddy, Vijay S , Barry, Michael A

Mayo Clinic

Viruses | February 17, 2022 | Volume: 14 | Issue: 2 | Pages: 414

10.3390/v14020414 | PMID 35216007 Get It

Various adenoviruses are being used as viral vectors for the generation of vaccines against chronic and emerging diseases (e.g., AIDS, COVID-19). Here, we report the improved capsid structure for one of these vectors, human adenovirus D26 (HAdV-D26), at 3.4 Å resolution, by reprocessing the previous cryo-electron microscopy dataset and obtaining a refined model. In addition to overall improvements in the model, the highlights of the structure include (1) locating a segment of the processed peptide of VIII that was previously believed to be released from the mature virions, (2) reorientation of the helical appendage domain (APD) of IIIa situated underneath the vertex region relative to its counterpart observed in the cleavage defective (ts1) mutant of HAdV-C5 that resulted in the loss of interactions between the APD and hexon bases, and (3) the revised conformation of the cleaved N-terminal segments of pre-protein VI (pVIn), located in the hexon cavities, is highly conserved, with notable stacking interactions between the conserved His13 and Phe18 residues. Taken together, the improved model of HAdV-D26 capsid provides a better understanding of protein–protein interactions in HAdV capsids and facilitates the efforts to modify and/or design adenoviral vectors with altered properties. Last but not least, we provide some insights into clotting factors (e.g., FX and PF4) binding to AdV vectors.
Sex‐related differences in the trends and outcomes of trans‐septal transcatheter mitral valve replacement: Insights from the National Readmissions Database
Elbadawi, Ayman , Tan, Bryan E‐Xin , Saad, Marwan , Sharaf, Barry L., Gordon, Paul , Saad, Marwan , Tan, Bryan E-Xin , Sammour, Yasser M. , Omer, Mohamed , Baron, Suzanne J. , Abbott, J. Dawn

Mayo Clinic

Catheterization and Cardiovascular Interventions | February 8, 2022 | Volume: 99 | Issue: 5 | Pages: 1636-1644

10.1002/ccd.30072 | PMID 35132765 Get It

AbstractBackgroundThere is a paucity of data regarding the sex‐related differences in the trends and outcomes of trans‐septal transcatheter mitral valve replacement (TS‐TMVR).MethodsThe Nationwide Readmissions Database (2015–2018) was queried for admissions for TS‐TMVR. Propensity matched analysis was conducted to compare outcomes with hospitalizations for TS‐TMVR among women versus men. The main study outcome was in‐hospital mortality.ResultsOur final analysis included 2063 hospitalizations for TS‐TMVR; of whom, 58.1% were women. The proportion of women among those undergoing TS‐TMVR increased from 50% in 2015 to 60.2% in 2018 (Ptrend = 0.04). Compared with men, women undergoing TS‐TMVR were slightly younger, and had a distinct profile of comorbidities. After matching, there was no significant difference in in‐hospital mortality among women versus men undergoing TS‐TMVR (7.8% vs. 6.1%, OR = 1.30; 95% CI: 0.79–2.13). Subgroup analyzes showed an interaction toward higher mortality with women versus men among patients with CKD (Pinteraction = 0.07). There were no significant differences between women and men in in‐hospital complications or length of stay after TS‐TMVR. Compared with men, women undergoing TS‐TMVR were more likely to be discharged to a nursing facility (17.7% vs. 11.5%, p = 0.01) and had higher rates of 30‐day readmissions (22.4% vs. 13.6%, p = 0.01).ConclusionThis nationwide analysis showed an increase in the proportion of women among patients undergoing TS‐TMVR during the study years. There were no differences in in‐hospital mortality, in‐hospital complications, or length of stay between both sexes following TS‐TMVR. Women were more likely to be discharged to nursing facilities and had higher rates of readmission at 30 days even after propensity matching.
Diabesity and heart failure with preserved ejection fraction: the picture is getting clearer
Jensen, Michael D. , Omar, Massar , Borlaug, Barry A.

Mayo Clinic

European Journal of Heart Failure | February 4, 2022 | Volume: 24 | Issue: 3 | Pages: 510-512

10.1002/ejhf.2440 | PMID 35118771 Get It

Histologic and proteomic remodeling of the pulmonary veins and arteries in a porcine model of chronic pulmonary venous hypertension
Fayyaz, Ahmed, Sabbah, Michael S. , Dasari, Surendra , DuBrock, Hilary M. , Charlesworth, M. Cristine , Borlaug, Barry A. , Jenkins, Sarah M. , Edwards, William D. , Redfield, Margaret M. , Fayyaz, Ahmed U., DuBrock, Hilary M , Charlesworth, M. Cristine , Borlaug, Barry A , Griffiths, Leigh G. , Wang, Ying

Mayo Clinic

Cardiovascular Research | January 10, 2022 | Volume: 119 | Issue: 1 | Pages: 268-282

10.1093/cvr/cvac005 | PMID 35022664 Get It

Abstract Aims In heart failure (HF), pulmonary venous hypertension (PVH) produces pulmonary hypertension (PH) with remodeling of pulmonary veins (PV) and arteries (PA). In a porcine PVH model, we performed proteomic-based bioinformatics to investigate unique pathophysiologic mechanisms mediating PA and PV remodeling. Methods and results Large PV were banded (PVH, n = 10) or not (Sham, n = 9) in piglets. At sacrifice, PV and PA were perfusion labelled for vessel-specific histology and proteomics. The PA and PV were separately sampled with laser-capture micro-dissection for mass spectrometry. Pulmonary vascular resistance [Wood Units; 8.6 (95% confidence interval: 6.3, 12.3) vs. 2.0 (1.7, 2.3)] and PA [19.9 (standard error of mean, 1.1) vs. 10.3 (1.1)] and PV [14.2 (1.2) vs. 7.6 (1.1)] wall thickness/external diameter (%) were increased in PVH (P &lt; 0.05 for all). Similar numbers of proteins were identified in PA (2093) and PV (2085) with 94% overlap, but biological processes differed. There were more differentially expressed proteins (287 vs. 161), altered canonical pathways (17 vs. 3), and predicted upstream regulators (PUSR; 22 vs. 6) in PV than PA. In PA and PV, bioinformatics indicated activation of the integrated stress response and mammalian target of rapamycin signalling with dysregulated growth. In PV, there was also activation of Rho/Rho-kinase signalling with decreased actin cytoskeletal signalling and altered tight and adherens junctions, ephrin B, and caveolae-mediated endocytosis signalling; all indicating disrupted endothelial barrier function. Indeed, protein biomarkers and the top PUSR in PV (transforming growth factor-beta) suggested endothelial to mesenchymal transition in PV. Findings were similar in human autopsy specimens. Conclusion These findings provide new therapeutic targets to oppose pulmonary vascular remodeling in HF-related PH.
Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality
Verbrugge, Frederik H. , Omote, Kazunori , Reddy, Yogesh N.V. , Sorimachi, Hidemi, Obokata, Masaru , Borlaug, Barry A. , Nishimura, Rick , Borlaug, Barry A , Obokata, Masaru , Verbrugge, Frederik H

Mayo Clinic

European Heart Journal | December 27, 2021 | Volume: 43 | Issue: 20 | Pages: 1941-1951

10.1093/eurheartj/ehab911 | PMID 35139159 Get It

Abstract Background A substantial proportion of patients with heart failure (HF) with preserved ejection fraction (HFpEF) present with normal natriuretic peptide (NP) levels. The pathophysiology and natural history for this phenotype remain unclear. Methods and results Consecutive subjects undergoing invasive cardiopulmonary exercise testing for unexplained dyspnoea at Mayo Clinic in 2006–18 were studied. Heart failure with preserved ejection fraction was defined as a pulmonary arterial wedge pressure (PAWP) ≥15 mmHg (rest) or ≥25 mmHg (exercise). Patients with HFpEF and normal NP [N-terminal of the pro-hormone B-type natriuretic peptide (NT-proBNP) &lt; 125 ng/L] were compared with HFpEF with high NP (NT-proBNP ≥ 125 ng/L) and controls with normal haemodynamics. Patients with HFpEF and normal (n = 157) vs. high NP (n = 263) were younger, yet older than controls (n = 161), with an intermediate comorbidity profile. Normal NP HFpEF was associated with more left ventricular hypertrophy and worse diastolic function compared with controls, but better diastolic function, lower left atrial volumes, superior right ventricular function, and less mitral/tricuspid regurgitation compared with high NP HFpEF. Cardiac output (CO) reserve with exercise was preserved in normal NP HFpEF [101% predicted, interquartile range (IQR): 75–124%], but this was achieved only at the cost of higher left ventricular transmural pressure (LVTMP) (14 ± 6 mmHg vs. 7 ± 4 mmHg in controls, P &lt; 0.001). In contrast, CO reserve was decreased in high NP HFpEF (85% predicted, IQR: 59–109%), with lower LVTMP (10 ± 8 mmHg) compared with normal NP HFpEF (P &lt; 0.001), despite similar PAWP. Patients with high NP HFpEF displayed the highest event rates, but normal NP HFpEF still had 2.7-fold higher risk for mortality or HF readmissions compared with controls (hazard ratio: 2.74, 95% confidence interval: 1.02–7.32) after adjusting for age, sex, and body mass index. Conclusion Patients with HFpEF and normal NP display mild diastolic dysfunction and preserved CO reserve during exercise, despite marked elevation in filling pressures. While clinical outcomes are not as poor compared with patients with high NP, patients with normal NP HFpEF exhibit increased risk of death or HF readmissions compared with patients without HF, emphasizing the importance of this phenotype.
Epidemiology and outcomes of pulmonary hypertension in the cardiac intensive care unit
Jentzer, Jacob C. , Wiley, Brandon M. , Reddy, Yogesh N.V. , Solomon, Michael A. , Solomon, Michael A , Nishimura, Rick , Jentzer, Jacob C , Barnett, Christopher F. , Borlaug, Barry A.

Mayo Clinic

European Heart Journal. Acute Cardiovascular Care | December 22, 2021 | Volume: 11 | Issue: 3 | Pages: 230-241

10.1093/ehjacc/zuab127 | PMID 35064269 Get It

Abstract Aims Pulmonary hypertension (PH) has been consistently associated with adverse outcomes in hospitalized patients. Limited epidemiologic data exist regarding PH in the cardiac intensive care unit (CICU) population. Here, we describe the prevalence, aetiology, and outcomes of PH in the CICU. Methods and results Cardiac intensive care unit patients admitted from 2007 to 2018 who had right ventricular systolic pressure (RVSP) measured via transthoracic echocardiography near CICU admission were included. PH was defined as RVSP &gt;35 mmHg, and moderate-to-severe PH as RVSP ≥50 mmHg. Predictors of in-hospital mortality were determined using multivariable logistic regression. Among 5042 patients (mean age 69.4 ± 14.8 years; 41% females), PH was present in 3085 (61%). The majority (68%) of patients with PH had left heart failure, and 29% had lung disease. In-hospital mortality occurred in 8.3% and was more frequent in patients with PH [10.9% vs. 4.2%, adjusted odds ratio (OR) 1.40, 95% confidence interval (CI) 1.03–1.92, P = 0.03], particularly patients with moderate-to-severe PH (14.4% vs. 6.2%, adjusted OR 1.65, 95% CI 1.27–2.14, P &lt; 0.001). In-hospital mortality increased incrementally as a function of higher RVSP (adjusted 1.18 per 10 mmHg increase, 95% CI 1.09–1.28, P &lt; 0.001). Patients with higher RVSP or moderate-to-severe PH had increased in-hospital mortality across admission diagnoses (all P &lt; 0.05). Conclusions Pulmonary hypertension is very common in the CICU population and appears to be independently associated with a higher risk of death during hospitalization, although the strength of this association varies according to the underlying admission diagnosis. These data highlight the importance of PH in patients with cardiac critical illness.